![New Trial Assesses Ivermectin`s Effect on COVID Patients New Trial Assesses Ivermectin`s Effect on COVID Patients](https://images.medindia.net/health-images/1200_1000/anti-covid-drug-2-dg.jpg)
‘New trial assesses the effect of Ivermectin, the anti-parasitic drug against COVID-19, and whether there are benefits or harms associated with its use.
’
Read More..Tweet it Now
The World Health Organization in March and the US Food and Drug Administration (FDA) had, in April last year, recommended against the use of ivermectin in treating COVID patients. The WHO said there was a "very low certainty of evidence" on ivermectin’s effects on mortality, hospital admission and getting rid of the virus from the body. Read More..
"Safety and efficacy are important when using any drug for a new indication. @WHO recommends against the use of ivermectin for #COVID19 except within clinical trials," Soumya Swaminathan, the global health body’s chief scientist, said in a tweet.
However, ivermectin has been taken up by doctors and by individuals self-medicating in countries, including Brazil, Bolivia, Peru and South Africa.
"Ivermectin is readily available globally, has been in wide use for many other infectious conditions so it’s a well-known medicine with a good safety profile, and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries," said Professor Chris Butler, from the University Oxford’s Nuffield Department of Primary Care Health Sciences, said in a statement.
"By including ivermectin in a large-scale trial, we hope to generate robust evidence to determine how effective the treatment is against COVID-19, and whether there are benefits or harms associated with its use," he added.
Advertisement
People aged 18 to 64 with certain underlying health conditions or shortness of breath from Covid-19, or aged over 65, are eligible to join the trial within the first 14 days of experiencing Covid-19 symptoms or receiving a positive test.
Advertisement
The trial can be joined easily from anywhere in the UK either online, over the telephone or via a GP practice, and without the need for face-to-face visits with the trial team in Oxford.
Source-IANS